ArticleCurrent medical mycology2015
Lamisil, a potent alternative antifungal drug for otomycosis.
Article in Current medical mycology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
- Molecular Identification and Antifungal Susceptibility of Yeasts and Molds Isolated from Patients with Otomycosis.Mycopathologia · 2021Article
- Antifungal susceptibility profiles of otomycosis etiological agents in Ahvaz, Iran.Current medical mycology · 2020Article
- Outer Ear Infections in Iran: A Review.Open access Macedonian journal of medical sciences · 2019Review
- Colonization and antifungals susceptibility patterns of Candida species isolated from hospitalized patients in ICUs and NICUs.Journal of nephropathology · 2015Article
- Otomycosis in iran: a review.Mycopathologia · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeOtomycosis is an acute, subacute or chronic fungal infection of the pinna, the external auditory meatus and the ear canal caused mainly by several species of saprophytic fungi. Lamisil (Terbinafine) is an allylamine antifungal agent, that is used both in the topical and oral administration for the treatment of dermatophytosis, cutaneous candidiasis, and the pityriasis versicolor. We investigated the MATERIALS AND
methodsFifteen clinically obtained isolates from otomycosis (
resultsOut of 23 isolates of
conclusionThis is a new approach for the possible use of Lamisil for the treatment of otomycosis
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.